SARS-like WIV1-CoV poised for human emergence.
- Menachery VD Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;
- Yount BL Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;
- Sims AC Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;
- Debbink K Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;
- Agnihothram SS Division of Microbiology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR 72079;
- Gralinski LE Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;
- Graham RL Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;
- Scobey T Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;
- Plante JA Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;
- Royal SR Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;
- Swanstrom J Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;
- Sheahan TP Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;
- Pickles RJ Division of Microbiology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR 72079; Department of Cell Biology and Physiology and Marsico Lung Institute/Cystic Fibrosis Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;
- Corti D Institute for Research in Biomedicine, Bellinzona, Switzerland; Institute of Microbiology, Eidgenössische Technische Hochschule Zurich, Zurich, Switzerland; Humabs BioMed SA, Bellinzona, Switzerland;
- Randell SH Department of Cell Biology and Physiology and Marsico Lung Institute/Cystic Fibrosis Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;
- Lanzavecchia A Institute for Research in Biomedicine, Bellinzona, Switzerland; Institute of Microbiology, Eidgenössische Technische Hochschule Zurich, Zurich, Switzerland;
- Marasco WA Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute-Department of Medicine, Harvard Medical School, Boston MA 02215.
- Baric RS Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599; Division of Microbiology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR 72079; rbaric@email.unc.edu.
- 2016-03-16
Published in:
- Proceedings of the National Academy of Sciences of the United States of America. - 2016
CoV
SARS
Spike
WIV1
emergence
Animals
Antibodies, Monoclonal
Antibodies, Neutralizing
Antibodies, Viral
Cells, Cultured
Chiroptera
Chlorocebus aethiops
Communicable Diseases, Emerging
Coronaviridae
Coronaviridae Infections
Cross Reactions
Encephalitis, Viral
Epithelial Cells
Host Specificity
Humans
Lung
Mice
Mice, Inbred BALB C
Mice, Transgenic
Models, Molecular
Peptidyl-Dipeptidase A
Point Mutation
Protein Conformation
Receptors, Virus
Recombinant Fusion Proteins
SARS Virus
Species Specificity
Spike Glycoprotein, Coronavirus
Vero Cells
Virus Replication
Zoonoses
English
Outbreaks from zoonotic sources represent a threat to both human disease as well as the global economy. Despite a wealth of metagenomics studies, methods to leverage these datasets to identify future threats are underdeveloped. In this study, we describe an approach that combines existing metagenomics data with reverse genetics to engineer reagents to evaluate emergence and pathogenic potential of circulating zoonotic viruses. Focusing on the severe acute respiratory syndrome (SARS)-like viruses, the results indicate that the WIV1-coronavirus (CoV) cluster has the ability to directly infect and may undergo limited transmission in human populations. However, in vivo attenuation suggests additional adaptation is required for epidemic disease. Importantly, available SARS monoclonal antibodies offered success in limiting viral infection absent from available vaccine approaches. Together, the data highlight the utility of a platform to identify and prioritize prepandemic strains harbored in animal reservoirs and document the threat posed by WIV1-CoV for emergence in human populations.
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.1073/pnas.1517719113
- PMID 26976607
- Persistent URL
- https://sonar.ch/global/documents/293249
Statistics
Document views: 53
File downloads:
- Full-text: 0